Significant reduction seen in secondary outcome of long-term depression but not in medium-term depression
Highest rates seen during COVID-19 pandemic versus before pandemic and in females, those aged 14 to 17 and 18 to 22 years
Additionally, a higher prevalence of lifetime suicide plan and attempts was observed
Small, but significant effects seen at six months and sustained at 12 months
Findings seen for attention-deficit/hyperactivity disorder or depressive disorder
Estimated percentage eligible ranges from 24 to 62 percent depending on eligibility criteria used
No increase observed in diagnoses following onset of COVID-19, but increase seen in proportion of women filling benzodiazepine prescription
Patients with CRS have increased risk for developing common psychiatric disorders and vice versa
Medication does not increase risk for depression, suicidal thoughts or behaviors among adults without known major psychopathology